LABCORP HOLDINGS INC. Reports Material Event

Labcorp Holdings Inc. reported that board member Dr. D. Gary Gilliland has decided to retire from its Board of Directors.

Rhea-AI Filing Summary

Labcorp Holdings Inc. reported that board member Dr. D. Gary Gilliland has decided to retire from its Board of Directors. The company received his notice on December 5, 2025, and his retirement will be effective December 31, 2025. Labcorp later issued a press release on December 10, 2025 to publicly announce his upcoming departure, and that release is included as an exhibit to this report.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Labcorp Holdings Inc. (LH) announce?

Labcorp Holdings Inc. announced that Dr. D. Gary Gilliland will retire from its Board of Directors, with his retirement effective December 31, 2025.

When did Dr. D. Gary Gilliland notify Labcorp (LH) of his retirement from the board?

Dr. Gilliland notified the Labcorp Board of his decision to retire on December 5, 2025.

When will Dr. Gilliland’s retirement from the Labcorp board become effective?

His retirement from the Board of Directors will become effective on December 31, 2025.

Did Labcorp (LH) issue a press release about the board retirement?

Yes. Labcorp issued a press release on December 10, 2025 announcing Dr. Gilliland’s retirement, which is included as Exhibit 99.1.

What exhibits are attached to this Labcorp (LH) Form 8-K?

The exhibits include Exhibit 99.1, a press release dated December 10, 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.

Which exchange is Labcorp (LH) common stock listed on?

Labcorp’s common stock, with trading symbol LH, is listed on the New York Stock Exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/10/2025 - 04:23 PM EST Learn about SEC filing dates

0000920148false00009201482025-12-052025-12-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

December 5, 2025

(Date of earliest event reported)

LABCORP HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

1-11353

99-2588107

(State or other jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

358 South Main Street

Burlington

,

North Carolina

27215

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number including area code) 336-229-1127

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, $0.10 par value

LH

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).             

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 5.02			Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 5, 2025, Dr. D. Gary Gilliland notified the Board of Directors (the “Board”) of Labcorp Holdings Inc. (the “Company”) of his decision to retire from the Board, effective December 31, 2025.
Item 7.01			Regulation FD Disclosure.
On December 10, 2025, the Company issued a press release announcing Dr. Gilliland’s retirement from the Board. A copy of that press release is attached to, and incorporated by reference into, this current report as Exhibit 99.1.

Item 9.01			Financial Statements and Exhibits.
Exhibit			Exhibit Name
Exhibit 99.1			Press Release dated December 10, 2025 issued by the Company
Exhibit 104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.

Registrant

Date: December 10, 2025			By:			/s/ SANDRA D. VAN DER VAART
						Sandra D. van der Vaart
						Executive Vice President, Chief Legal Officer and Corporate Secretary